CNS Candidates Mostly Offer New Approaches In Established Categories
This article was originally published in Pharmaceutical Approvals Monthly
CNS candidates range from new mechanisms in multiple sclerosis to the first orexin antagonist for insomnia and refinements in neurotransmitter targeting for schizophrenia and depression. A second amyloid imaging agent could reach the market to aid in diagnosis of Alzheimer’s disease.
You may also be interested in...
Russell Katz will retire following a 30-year career at FDA; his departure comes as the agency is embarking on new efforts to encourage drug development for Alzheimer’s disease and amyotrophic lateral sclerosis.
December’s Arthritis Advisory Committee review of Hemispherx’s drug provided FDA with the first public opportunity to explain in detail why the chronic fatigue syndrome drug, in development for almost 25 years, has not passed regulatory muster to date.
The company says a data formatting issue was the reason FDA declined to accept the supplemental application for alemtuzumab for relapsing multiple sclerosis.